These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
640 related articles for article (PubMed ID: 28619476)
1. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Kanes S; Colquhoun H; Gunduz-Bruce H; Raines S; Arnold R; Schacterle A; Doherty J; Epperson CN; Deligiannidis KM; Riesenberg R; Hoffmann E; Rubinow D; Jonas J; Paul S; Meltzer-Brody S Lancet; 2017 Jul; 390(10093):480-489. PubMed ID: 28619476 [TBL] [Abstract][Full Text] [Related]
2. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Meltzer-Brody S; Colquhoun H; Riesenberg R; Epperson CN; Deligiannidis KM; Rubinow DR; Li H; Sankoh AJ; Clemson C; Schacterle A; Jonas J; Kanes S Lancet; 2018 Sep; 392(10152):1058-1070. PubMed ID: 30177236 [TBL] [Abstract][Full Text] [Related]
3. Brexanolone for postpartum depression. Hutcherson TC; Cieri-Hutcherson NE; Gosciak MF Am J Health Syst Pharm; 2020 Feb; 77(5):336-345. PubMed ID: 32073124 [TBL] [Abstract][Full Text] [Related]
4. Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression. Kanes SJ; Colquhoun H; Doherty J; Raines S; Hoffmann E; Rubinow DR; Meltzer-Brody S Hum Psychopharmacol; 2017 Mar; 32(2):. PubMed ID: 28370307 [TBL] [Abstract][Full Text] [Related]
5. Brexanolone for Postpartum Depression: Clinical Evidence and Practical Considerations. Leader LD; O'Connell M; VandenBerg A Pharmacotherapy; 2019 Nov; 39(11):1105-1112. PubMed ID: 31514247 [TBL] [Abstract][Full Text] [Related]
6. Using Matching-Adjusted Indirect Comparisons and Network Meta-analyses to Compare Efficacy of Brexanolone Injection with Selective Serotonin Reuptake Inhibitors for Treating Postpartum Depression. Cooper MC; Kilvert HS; Hodgkins P; Roskell NS; Eldar-Lissai A CNS Drugs; 2019 Oct; 33(10):1039-1052. PubMed ID: 31642037 [TBL] [Abstract][Full Text] [Related]
7. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders. Walkery A; Leader LD; Cooke E; VandenBerg A Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503 [TBL] [Abstract][Full Text] [Related]
8. Trial of SAGE-217 in Patients with Major Depressive Disorder. Gunduz-Bruce H; Silber C; Kaul I; Rothschild AJ; Riesenberg R; Sankoh AJ; Li H; Lasser R; Zorumski CF; Rubinow DR; Paul SM; Jonas J; Doherty JJ; Kanes SJ N Engl J Med; 2019 Sep; 381(10):903-911. PubMed ID: 31483961 [TBL] [Abstract][Full Text] [Related]
9. Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression. Powell JG; Garland S; Preston K; Piszczatoski C Ann Pharmacother; 2020 Feb; 54(2):157-163. PubMed ID: 31476884 [No Abstract] [Full Text] [Related]
10. Brexanolone for postpartum depression: A meta-analysis of randomized controlled studies. Zheng W; Cai DB; Zheng W; Sim K; Ungvari GS; Peng XJ; Ning YP; Wang G; Xiang YT Psychiatry Res; 2019 Sep; 279():83-89. PubMed ID: 31323375 [TBL] [Abstract][Full Text] [Related]
11. Brexanolone: First Global Approval. Scott LJ Drugs; 2019 May; 79(7):779-783. PubMed ID: 31006078 [TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development. Frieder A; Fersh M; Hainline R; Deligiannidis KM CNS Drugs; 2019 Mar; 33(3):265-282. PubMed ID: 30790145 [TBL] [Abstract][Full Text] [Related]
13. Novel Augmentation Strategies in Major Depression. Martiny K Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173 [TBL] [Abstract][Full Text] [Related]
15. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901 [TBL] [Abstract][Full Text] [Related]
16. Brexanolone For Postpartum Depression: A Novel Approach and a Call for Comprehensive Postpartum Care. Jarman AF; MacLean JV; Barron RJ; Wightman RS; McGregor AJ Clin Ther; 2020 Jan; 42(1):231-235. PubMed ID: 31910998 [TBL] [Abstract][Full Text] [Related]
17. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823 [TBL] [Abstract][Full Text] [Related]
18. US Food and Drug Administration approval of esketamine and brexanolone. Cristea IA; Naudet F Lancet Psychiatry; 2019 Dec; 6(12):975-977. PubMed ID: 31680013 [No Abstract] [Full Text] [Related]
19. An update on approved and emerging drugs for the treatment of postpartum depression. Çulcu EA; Demiryürek Ş; Demiryürek AT Ideggyogy Sz; 2024 Jul; 77(7-8):227-235. PubMed ID: 39082257 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of a single low dose of esketamine after childbirth for mothers with symptoms of prenatal depression: randomised clinical trial. Wang S; Deng CM; Zeng Y; Chen XZ; Li AY; Feng SW; Xu LL; Chen L; Yuan HM; Hu H; Yang T; Han T; Zhang HY; Jiang M; Sun XY; Guo HN; Sessler DI; Wang DX BMJ; 2024 Apr; 385():e078218. PubMed ID: 38808490 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]